Study identifier:D702EC00001
ClinicalTrials.gov identifier:NCT07161414
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase I, Multicenter, Dose Finding and Dose Confirmation Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants with Advanced Solid Tumors Previously Treated with Standard of Care Therapy (ARTEMIDE-subQ)
Advanced Solid Tumors, Gastroesophageal Junction Adenocarcinoma
Phase 1
no
Rilvegostomig, Recombinant Human Hyaluronidase, IV Rilvegostomig, Recombinant Human Hyaluronidase (rHu), SC Rilvegostomig, SC rilvegostomig + rHu
All
40
Interventional
18 Years - 130 Years
Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel
Masking: -
Primary Purpose: Treatment
Verified 01 Oct 2027 by AstraZeneca
AstraZeneca
PAREXEL
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: Part 1 (dose finding): Cohort A - SC Rilvegostomig Dose Level 1 (DL1) and rHu Participants will receive IV rilvegostomig (Dose X) as their first dose of study treatment, followed by subsequent treatments with recombinant human hyaluronidase (rHu) and SC rilvegostomig (DL1) at predefined intervals. | Drug: IV Rilvegostomig Rilvegostomig administered IV. Other Name: AZD2936 Drug: Recombinant Human Hyaluronidase (rHu) rHu administered subcutaneously. Drug: SC Rilvegostomig Rilvegostomig administered subcutaneously. Other Name: AZD2936 |
| Experimental: Part 1 (dose finding): Cohort B - SC Rilvegostomig DL2 and rHu Participants will receive IV rilvegostomig (Dose X) as their first dose of study treatment, followed by subsequent treatments with rHu and SC rilvegostomig (DL2) at predefined intervals. | Drug: IV Rilvegostomig Rilvegostomig administered IV. Other Name: AZD2936 Drug: Recombinant Human Hyaluronidase (rHu) rHu administered subcutaneously. Drug: SC Rilvegostomig Rilvegostomig administered subcutaneously. Other Name: AZD2936 |
| Experimental: Part 2 (dose confirmation): SC Rilvegostomig and rHu Participants will receive SC rilvegostomig and rHu. | Drug: SC rilvegostomig + rHu SC rilvegostomig + rHu administered subcutaneously. |
| Advanced solid tumors, pre-treated Adult participants with advanced solid tumors previously treated with standard of care therapy for whom IO monotherapy would be deemed appropriate by the investigator. | - |
| Experimental: Cohort A: Dose Level 1 (DL1) Participants will receive IV rilvegostomig 750 mg for Cycle 1. From Cycle 2 onward, participants will receive SC rHu followed by SC rilvegostomig 1000 mg Q3W up to Cycle 35 or until unacceptable toxicity or disease progression. Approximately 10 participants. | - |
| Experimental: Cohort B: Dose Level 2 (DL2) Participants will receive IV rilvegostomig 750 mg for Cycle 1. From Cycle 2 onward, participants will receive SC rHu followed by SC rilvegostomig 1500 mg Q3W up to Cycle 35 or until unacceptable toxicity or disease progression. This dose might be adjusted. Approximately 10 participants. | - |
| Experimental: Part 2: Dose Confirmation Participants will receive SC rilvegostomig co-formulated with rHu at a flat dose Q3W until a maximum of 35 cycles or until unacceptable toxicity or disease progression. A flat dose of rilvegostomig for SC administration as a co-formulation with rHu will be determined based on Part 1 data. Approximately 20 participants. | - |